phenyl ether has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, H; Chen, J; Cheng, B; Liu, T | 1 |
| Breuer, E; Chernilovsky, T; Frant, J; Hoffman, A; Nedvetzki, S; Reich, R; Vaksman, O; Veerendhar, A | 1 |
2 other study(ies) available for phenyl ether and B16 Melanoma
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Topics: A549 Cells; Animals; Antineoplastic Agents; B7-H1 Antigen; Coculture Techniques; Dose-Response Relationship, Drug; HeLa Cells; Hep G2 Cells; Humans; Jurkat Cells; Male; MCF-7 Cells; Melanoma, Experimental; Mice; Molecular Docking Simulation; Phenyl Ethers; Programmed Cell Death 1 Receptor; Resorcinols | 2021 |
Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cobamides; Cyclohexanes; Enzyme Inhibitors; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Melanoma, Experimental; Mice; Organophosphonates; Phenyl Ethers; Protein Isoforms; Rats | 2011 |